The Granata Bio Team

  • Marc Chung is a Co-Founder of Granata Bio, where he leads strategic planning, partnerships, and business development to drive growth and long-term value. With extensive experience in healthcare consulting, analytics, and account strategy, including roles at IQVIA, Outcome Health, and Komodo Health, Marc bridges deep industry insight with commercial strategy to help bring innovative reproductive therapies to market. He holds a BA from Johns Hopkins University and an MBA from Yale School of Management. Learn more and connect with Marc on LinkedIn.

  • With more than two decades of experience in gynecology and assisted reproductive technologies, Dr. Barbara Cometti leads the scientific affairs strategy at Granata Bio. She oversees program design, translational research, and regulatory alignment to drive the development of novel fertility therapies. Prior to joining Granata Bio, Barbara was Senior R&D Scientific Affairs Manager at IBSA Institut Biochimique, where she guided ART programs and published important work on fertility hormone clinical studies and reproductive endocrinology. Learn more and connect with Barbara on LinkedIn.​

    ​

  • Shelly Frazier supports Granata Bio’s leadership as Executive Coordinator & Quality Assurance Administrator, ensuring operational efficiency, cross-functional alignment, and process rigor. With nearly two decades of previous administrative and project leadership experience at EMD Serono, she brings organizational discipline, attention to detail, and a collaborative mindset to every aspect of her role. Learn more and connect with Shelly on LinkedIn.

  • As Head of Commercial Operations at Granata Bio, Sierra Cristiano shapes the commercial infrastructure and strategic launch readiness of fertility-focused therapies. She teams experience in global pharmaceutical innovation and commercial operations with strong cross-functional leadership in strategy, marketing, partner engagement, and execution to help Granata Bio deliver on its mission of reimagining what’s possible in reproductive health. Learn more and connect with Sierra on LinkedIn.

  • As Product Development Manager at Granata Bio, Leigh plays a key role in advancing clinical and drug development programs from early research through late-stage trials. She applies a strong foundation in biological research, project coordination, and cross-functional execution to her role, developing strategic plans, driving program operations, and ensuring alignment across internal teams, external partners, and regulatory requirements. Prior to joining Granata Bio, she supported molecular biology research programs at MIT, Dartmouth College, and the Howard Hughes Medical Institute, where she helped establish new lab operations and streamline experimental workflows. Leigh holds a BS in Biology from Merrimack College. Learn more and connect with Leigh on LinkedIn.

  • Sarah Faranda is Co-Founder and Chief Development Officer of Granata Bio, where she shapes the company’s development and commercial initiatives in fertility and women’s health. With over 14 years of strategic marketing experience across global and U.S. pharmaceutical brands, Sarah previously led launches and brand transformations for Teva Women’s Health, Ferring Fertility and EMD Serono. Learn more and connect with Sarah on LinkedIn.

  • In this role as Chief Operating Officer, Steve applies more than 20 years of operational leadership and commercial strategy experience to oversee operations, business development, and growth initiatives that drive execution across commercialization and day-to-day business performance. He also sits on the board of directors for Granata Bio's partner organizations, Oviva Therapeutics and GTE Bio, LLC, where he provides strategic and operational guidance to progress new early-stage therapeutic options within the Women's Health Industry. Learn more and connect with Steve on LinkedIn.

  • As Director of Product Development at Granata Bio, Stephanie Moebius drives strategies that align regulatory, CMC, clinical, and commercial priorities as the company advances new therapies toward market. Her deep experience across product development, marketing, and market access, combined with a collaborative, influential approach, enables Stephanie to integrate scientific rigor with commercial insight, build consensus among diverse teams, and translate strategic priorities into measurable impact. Learn more and connect with Stephanie on LinkedIn.

  • Dave Paller is CFO and Co-Founder of Granata Bio, where he leads business development, financial operations, and strategic planning to support the company’s mission of expanding access to fertility therapeutics. With a background in bioengineering, medical-device development, and academic research, Dave bridges scientific insight with commercial strateg to help turn innovative reproductive-health concepts into viable, patient-centered solutions. Learn more and connect with Dave on LinkedIn.

  • As CEO and Co-Founder of Granata Bio, Evan leads the company’s mission to bring innovation back to reproductive health. He combines experience across biotech, pharma, and medical devices with a proven track record in product launch, commercialization, and growth strategy to expand access to fertility care. Learn more and connect with Evan on LinkedIn.

  • In this role as Chief Operating Officer, Steve applies more than 20 years of operational leadership and commercial strategy experience to oversee operations, business development, and growth initiatives that drive execution across commercialization and day-to-day business performance. He also sits on the board of directors for Granata Bio's partner organizations, Oviva Therapeutics and GTE Bio, LLC, where he provides strategic and operational guidance to progress new early-stage therapeutic options within the Women's Health Industry. Learn more and connect with Steve on LinkedIn.

  • As Director of Product Development at Granata Bio, Stephanie Moebius drives strategies that align regulatory, CMC, clinical, and commercial priorities as the company advances new therapies toward market. Her deep experience across product development, marketing, and market access, combined with a collaborative, influential approach, enables Stephanie to integrate scientific rigor with commercial insight, build consensus among diverse teams, and translate strategic priorities into measurable impact. Learn more and connect with Stephanie on LinkedIn.

  • Dave Paller is CFO and Co-Founder of Granata Bio, where he leads business development, financial operations, and strategic planning to support the company’s mission of expanding access to fertility therapeutics. With a background in bioengineering, medical-device development, and academic research, Dave bridges scientific insight with commercial strateg to help turn innovative reproductive-health concepts into viable, patient-centered solutions. Learn more and connect with Dave on LinkedIn.

  • As CEO and Co-Founder of Granata Bio, Evan leads the company’s mission to bring innovation back to reproductive health. He combines experience across biotech, pharma, and medical devices with a proven track record in product launch, commercialization, and growth strategy to expand access to fertility care. Learn more and connect with Evan on LinkedIn.